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Abstract: Biophysical and structural investigations are presented with a focus on the membrane
lipid interactions of cationic linear antibiotic peptides such as magainin, PGLa, LL37, and melittin.
Observations made with these peptides are distinct as seen from data obtained with the hydrophobic
peptide alamethicin. The cationic amphipathic peptides predominantly adopt membrane alignments
parallel to the bilayer surface; thus the distribution of polar and non-polar side chains of the
amphipathic helices mirror the environmental changes at the membrane interface. Such a membrane
partitioning of an amphipathic helix has been shown to cause considerable disruptions in the lipid
packing arrangements, transient openings at low peptide concentration, and membrane disintegration
at higher peptide-to-lipid ratios. The manifold supramolecular arrangements adopted by lipids and
peptides are represented by the ‘soft membranes adapt and respond, also transiently’ (SMART)
model. Whereas molecular dynamics simulations provide atomistic views on lipid membranes
in the presence of antimicrobial peptides, the biophysical investigations reveal interesting details
on a molecular and supramolecular level, and recent microscopic imaging experiments delineate
interesting sequences of events when bacterial cells are exposed to such peptides. Finally, biophysical
studies that aim to reveal the mechanisms of synergistic interactions of magainin 2 and PGLa are
presented, including unpublished isothermal titration calorimetry (ITC), circular dichroism (CD)
and dynamic light scattering (DLS) measurements that suggest that the peptides are involved in
liposome agglutination by mediating intermembrane interactions. A number of structural events
are presented in schematic models that relate to the antimicrobial and synergistic mechanism of
amphipathic peptides when they are aligned parallel to the membrane surface.
Keywords: magainin; cecropin; membrane topology; local disorder; membrane pore; membrane
macroscopic phase; soft membrane adapt and respond, also transiently (SMART) model; carpet model;
toroidal pore; peptide-lipid interactions
1. Introduction
Antimicrobial peptides (AMPs) are effectors of the innate immune system which provide
a first line of defense against a multitude of pathogenic microorganisms. Higher organisms release
AMPs immediately when infections by bacteria or fungi occur [1,2]. They have been found in
a wide variety of species from the plant and animal kingdom, including humans [3]. Furthermore,
many peptides produced by microorganisms have been identified and investigated [4,5]. After their
first discovery decades ago [6–8], many new sequences have been added to the corresponding data
bases [9,10] and they have been investigated by a wide variety of techniques to better understand their
mechanisms of action. Since the worldwide re-emergence of infectious diseases and a rapid increase in
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multi-resistant pathogens [11] they bear great promise to lead the way to new classes of antibiotics
capable of counteracting the continuously increasing threat by resistant microorganisms; thus the
declining number of effective pharmaceutical agents can be complemented. Whereas many natural
peptides have potential topical applications, they are considered unsuitable for oral intake because
of their fast degradation by proteases. However, peptides can be modified and made unavailable
during transport by incorporation into nanostructures or by fixation to surfaces [12–14], thus they are
protected and able to reach their target. Alternatively, understanding the mechanism of action of the
natural sequences paves the way to designing molecules with favorable properties that mirror the
essential characteristics of the template compounds. Therefore, the study of antimicrobial peptides
(AMPs), which have evaded bacterial resistance during millions of years of evolution [2], promises to
reveal novel strategies for the development of new lines of antibiotics.
The physico-chemical characteristics of antimicrobial peptides discussed in this paper in
combination with a multitude of investigations indicates that they interact with lipid bilayers and
interfere with the barrier function of bacterial membranes. In contrast, molecules that specifically target
proteinaceous receptors can be made inefficient by mutagenesis of one or a few sites, and it is much
less likely that bacteria develop resistance to compounds whose primary target is the destruction
of the physico-chemical properties of the lipid membrane [15]. Membrane-active peptides exhibit
a wide range of structural features some being helical in their bilayer-associated state [16,17],
others forming cyclic [18–21] and/or β-sheet arrangements [22–26]. Indeed, following the insights
gained from the studies of cationic amphipathic antimicrobial peptides a number of small amphipathic
molecules [27,28], pseudopeptides [21,29–36], and polymers [37] have been designed and investigated,
and found to also exhibit potent antimicrobial activities.
Here, some of the underlying research efforts shall be presented that have led to important
mechanistic insights and the design of new compounds. The review focuses on linear cationic peptides
such as magainins [38], cecropins and designed peptides [39–41] (amino acid sequences are provided in
Table 1), antimicrobial peptides which have been described and investigated early on. In the following,
insights with these AMPs provided guidelines for the design of new compounds and initiated the
search for, and investigation of, related sequences. Despite decades of research, new structural
and dynamic features of membrane-associated AMPs are continuously being discovered [26,42]
because these peptides can adopt a large diversity of conformations and topologies whose exchanges
and interactions are governed by multiple equilibria [43]. Finally, the synergistic interactions
between PGLa and magainins will be discussed because the covalent or non-covalent combination
of compounds provides an alternative strategy to enhance their efficiency and further reduces their
susceptibility to bacterial resistance.
Table 1. Sequences of peptides discussed in this paper. The one-letter code is used for peptides made
from conventional amino acids only. The alamethicin sequence is given by the three-letter code with the
following non-standard residues: Aib: α-aminoisobutyric acid, Phl: L-phenylalaninol, Ac- for acetyl-
and -NH2 for the carboxamide terminus, respectively.
magainin 2 GIGKF LHSAK KFGKA FVGEI MNS
PGLa GMASK AGAIA GKIAK VALKA L-NH2
cecropin A KWKLF KKIEK VGQNI RDGII KAGPA VAVVG QATQI AK-NH2
LL37 LLGDF FRKSK EKIGK EFKRI VQRIK DFLRN LVPRT ES
melittin GIGAV LKVLT TGLPA LISWI KRKRQ Q-NH2
LAH4 KKALL ALALH HLAHL ALHLA LALKK A-NH2
alamethicin (F50/7) Ac-Aib-Pro-Aib-Ala-Aib-Aib-Gln-Aib-Val-Aib-Gly-Leu-Aib-Pro-Val-Aib-Aib-Gln-Gln-Phl
Peptides from frogs and insects have already been described in the 1960s [7,44], while magainins
and cecropins, which act as specific antimicrobial compounds, have been discovered with some
delay [2,45]. These sequences are linear, highly cationic, and form amphipathic helices when
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interacting with membranes. They are thought to specifically disrupt the integrity of bacterial and
fungal membranes by insertion, thereby inhibiting the growth of microorganisms and/or enter into
the cell interior [46]. Thereby, they constitute a first line of defense when infections occur [2,45].
By also modulating the immune response of the host organisms, their efficiency is considerably
enhanced, and because of this extension of functionalities, it has been suggested to rename them as
‘host defense peptides’ [47–50]. Indeed, metabolomics studies reveal complex reactions by the bacterial
cells when exposed to AMPs, many being unique to a specific sequence [51,52].
Magainins and derivatives thereof have been extensively studied by biophysical approaches
(e.g., [53–57]), with sometimes unexpected results, and the insights thus obtained have formed the
basis for suggesting novel mechanisms of action of these peptides [43,58]. When added to membranes,
magainins and cecropins were found to exhibit lytic activities. In some electrophysiological
experiments, they also showed discrete multi-level conductivities [59–62], which in analogy to models
that had been proposed for the hydrophobic alamethicin peptide or for large helical channel proteins,
was taken as an indicator for transmembrane helical bundle formation [63]. However, it is important
to emphasize that unlike the alamethicin channels, those recorded in the presence of magainins or
cecropins are less well defined, erratic, and characterized by large variations [59–61]. These pronounced
differences in electrophysiological recordings reflect distinct physico-chemical properties of these
sequences, such as number of charges, hydrophobicity, and hydrophobic moment (Table 1).
Furthermore, magainin pore formation was investigated on a macroscopic scale by following the
kinetics of calcein release from individual giant unilamellar vesicles (GUV) made from defined mixture
of membrane lipids, dioleoylphosphatidylcholine/dioleoylphosphatidylglycerol DOPC/DOPG at
different molar ratios [64]. These experiments indicate that after addition of the peptide, it takes
minutes before the release of fluorophores sets in. Once the pores have been established, the vesicles,
which are several micrometers in size, empty within 30 s. Because the rate-limiting step is the
formation of the pore, rather than diffusion through the pore, magainin pore formation in GUVs
follows an all-or-nothing mechanism. This observation agrees with calcein release experiments from
suspensions of large unilamellar vesicles made from palmitoyl-oleoyl-phosphatidylcholine (POPC)
and palmitoyl-oleoyl-phosphatidylglycerol (POPG) lipid membranes [65]. Conversely, for magainin 2,
an all-or-nothing mechanism dominates in the presence of 50 mol % phosphatidylglycerol (PG) a more
graded release is observed when the PG content is reduced to 20 mol % [65]. These experiments showed
no indications of peptide oligomerization in either state [65]. The subsequent fluorophore release is
a two-stage process [66]. An initial fast release has been associated with magainin interacting with only
the outside monolayer, which causes an unbalance. Equilibration of the peptide concentration between
the outer and inner leaflets results in the transient formation of very large pores [66]. Thereafter,
smaller pores assure a slower release of fluorophore, but even these persistent openings are large
enough to allow for the passage of molecules with a hydrodynamic radius of 3 nm (equivalent to
a globular protein of molecular weight (MW) > 20 kDa) [66].
Recently, microscopic imaging techniques were introduced into the field, which reveal the
spatio-temporal binding of antimicrobial peptides to live bacteria and the related membrane
permeabilization events. For example, the human peptide LL37 preferentially attacks septating
Escherichia coli cells where the peptide is found associated with the septum and the curved regions of the
outer membrane [67]. In non-septating cells, it prefers to bind to one of the endcaps. Influx of the AMPs
to the periplasmic space results in cell shrinking, probably via an osmotic effect. After permeabilization
of the outer membrane, there is a short delay before cytoplasmatic membrane permeabilization occurs.
These openings of the outer and cytoplasmatic membranes are localized and persistent, rather than
global and transient [68]. Notably, whereas many events observed on this cellular level resemble
each other, the exact details vary with the antimicrobial compound when cationic polymers, longer or
shorter peptides such as LL37, cecropin A, or melittin are compared to each other [69]. Furthermore,
the events that happen with E. coli cells that are grown either under aerobic or anaerobic conditions
have been compared to each other and correlated with mutagenesis experiments [70]. This data
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suggests that LL37 specifically affects the electron transport chain [70]. Notably, the permeabilization
in the presence of alamethicin follows a different series of events, even though the data do not rule
out a chaotic pore or a carpet mechanisms for this hydrophobic peptide [71]. Whereas a chaotic pore
structure is shown in Figure 1A,B a peptide carpet is illustrated in reference [43].
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Figure 1. Schematic models illustrating how antimicrobial peptides work and interact with membranes
(A–D), and how two peptides can interact synergistically in a membrane environment (E–G).
(A) Peptides such as magainin partition into the membrane interface and cause disordering of the lipid
packing. (B) Bilayer openings form stochastically when the peptide concentration increases locally,
or when the membrane disrupts at high peptide-to-lipid ratios [72]. Along the openings, the peptides
can insert and cross in in-planar or at tilted alignments. (C) In molecular dynamics calculations
schematic, amphipathic helices have been simulated to form double belts [73], an arrangement which
also agrees with the in-planar alignment of the peptide helices observed by solid-state nuclear magnetic
resonance NMR spectroscopy [38]. (D) Fluorescence quenching experiments suggest mesophase
structures formed by in-plane oriented helices [74]. (E) The membrane disruptive properties of one
peptide (yellow) help the insertion of another one (blue), which by itself is less likely to partition into
membranes of high negative curvature [75]. (F) Peptide-peptide contacts result in the agglutination
of liposomes (Figure 3) [76], and could be responsible for synergistic enhancement of activities.
(G) A more densely packed mesophase arrangement forms in the presence of two peptides with
comple entary charge distribution such as magainin 2 and PGLa [77]. Notably, multiple mechanisms,
such as a combination of E, F, and G may apply. Panels A, B, E, and F show side views, panels C, D,
and G show top views of the lipid bilayer.
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Structural investigations show that the random coil structure of magainins in aqueous solution
becomes helical once the peptide inserts into membrane environments [72]. This conformational
transition has been identified to be a driving force of membrane association [78,79]. Importantly,
both circular dichroism (CD) and solid-state nuclear magnetic resonance (NMR) spectroscopy
on uniaxially oriented membranes indicate that the magainin helix is oriented parallel to the
membrane surface, which results in membrane association being reversible [38]. The in-planar
alignment has been confirmed for magainin 2 in membranes of different composition [38,54],
for magainin analogues [80,81] and for a number of other linear cationic antimicrobial peptides [82–86].
In contrast, alamethicin with its much different characteristics in both electrophysiological
recordings and physico-chemical properties (Table 1), has been found to form well-defined channels
(reviewed e.g., in [17,87]) and to adopt stable transmembrane helical alignments in canonical
dimyristoyl-phosphatidylcholine (DMPC) and (POPC) membranes [88–92]. However, even this
peptide adopts in-plane alignments under certain conditions [42,93] emphasizing the dynamic nature
of peptide-lipid interactions involving multiple equilibria [43]. CD spectroscopy has also been used to
study the association kinetics of magainin to whole cells and lipopolysaccharides [94].
When investigated in more detail, the topology of magainin 2 has been found to be parallel to
the membrane surface regardless of the lipid composition [38,54]. In contrast, a much wider range
of alignments has been observed for its relative, PGLa [95,96] (Table 1). Interestingly, the difference
becomes only apparent in membranes where both fatty acyl chains are saturated. For example,
in DMPC, PGLa changes its tilt angle by up to 30 degrees upon an increase in peptide concentration [97].
The transition occurs at 0.5 to 2 mol % depending on the membrane hydration conditions [95,97].
A continuous range of tilt angles was observed when saturated phosphatidylcholine (PC) bilayers
with decreasing hydrophobic thickness where investigated [95,96]. These studies reveal helical tilt
angles that are suggestive of transmembrane orientations when thin phosphatidylcholine bilayers
(C10 or C12 fatty acyl chains) are investigated [95]. When PGLa is studied in phospholipid bilayers
carrying unsaturations (such as palmitoyl-oleoyl-phospholipids), the peptide remains stably aligned
along the surface [38,95,98].
When an amphipathic peptide such as magainin resides in the bilayer interface, it pushes apart
the lipids at the level of the head group and glycerol regions [54], which loosens the packing of the
hydrophobic region (disordering effect, Figure 1A) [99,100]. The accompanying compensation by the
membrane lipids results in a reduction of the membrane thickness [57,101]. Deuterium solid-state
NMR measurements have indeed revealed a decrease of the order parameters in the bilayer interior
upon addition of magainin 2, PGLa, and other amphipathic peptides [99,102–104]. Notably, the bilayer
disruptive properties of such peptides have been estimated to cover a 50 Å radius [105,106].
The question arises for how in-plane oriented peptides can promote the passage of water, ions,
and fluorescence dyes across the lipid bilayer. Molecular dynamics simulations have provided
atomistic views on how this may be possible. They show not only the method by which hydrophobic
peptides insert into the membrane to form peptide channels made from transmembrane helical
arrangements [63], but also how in-plane oriented helices deform the lipid bilayer, and how their
side chains reach to the opposite bilayer leaflet of the membrane, thus resulting in the formation of
water-filled openings [73,107,108].
Lazaridis and co-workers report on 5–9 µs all-atom molecular dynamics simulations, starting
from tetrameric transmembrane helical bundles of magainin or PGLa in 80–120 lipids of DMPC or
DMPC/DMPG 3/1 [108]. During the simulations, the peptides lose their transmembrane orientation
and adopt tilted configurations where magainin also occurs as an antiparallel dimer (illustrated
in Figure 1B).
Furthermore, Vacha and coworkers present coarse-grained molecular dynamics (MD) of schematic
amphipathic peptides and find evidence for a novel double belt arrangement where peptides oriented
parallel to the bilayer plane form defined membrane openings (Figure 1C) [73]. The exact topology
depends on the length of the peptide and its hydrophobicity distribution, but also on the membrane
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thickness [109]. All-atom 100 ns simulations in palmitoyl-oleoyl-phosphatidylethanolamine/
palmitoyl-oleoyl-phosphatidylglycerol (POPE/POPG) 3/1 of one, two, or eight peptides and 512 lipids
show a stable in-plane topology of magainin and pleurocidin, some oligomerization, but no pore
or supramolecular rearrangement within this time frame [110]. Finally, recent simulation work
investigating magainin 2-lipopolysaccharide and ion interactions shall be mentioned [111].
Taken together, the molecular dynamics simulations provide a rather heterogeneous view of the
magainin membrane interactions, where, despite some peptide-peptide interactions, pores form
through stochastic rearrangements of peptides and lipids rather than through well-defined
channel structures (Figure 1B). Although this view is in good agreement with electrophysiological
recordings [59–62] the comparatively small size of the membrane patches and their relatively short
duration does not yet capture the membrane lytic nature of the peptides, or the large pores that become
apparent in dye release experiments [65,66].
Based on the GxxxG amino acid motif, which has been shown to be a dimer recognition
sequence for transmembrane helical domains [112], a symmetric antiparallel dimer of PGLa has
been assembled and then simulated by all-atom MD for up to 2 µs [113]. Although this time
frame is too short to follow larger supramolecular rearrangements or the dissociation of preformed
oligomers, the simulation provides interesting images of possible arrangements of PGLa in lipid
bilayers. Unfortunately, to our knowledge so far, experimental proof for dimer formation in membrane
environments such as solid-state NMR distance measurements is still missing, thus the exact reason for
the change in topology when the peptide concentration increases (cf. ultra) [95–97] remains a matter
of speculation. An interesting question in this context is the local environment of the GxxxG motif,
which to our knowledge has only been shown to drive dimerization within the hydrophobic core of
the membrane [112]. Dimerization thus assures that the polar backbone atoms of helical glycines are
shielded from the hydrophobic surroundings. Along this line, dimer formation is suggestive of a deep
membrane penetration of the PGLa helix, placing the two glycines in a non-polar environment.
The bilayer disruptive properties of amphipathic helices that are aligned along the membrane
interface, with some of the helical cross-section interacting with the hydrophobic fatty acyl chain and
the opposite face exposed to the polar head group, can be rationalized by the molecular shape concept
that has been originally introduced to explain the phase behavior of lipids [114,115]. Geometrical
considerations are used to explain why the cylindrical PC lipids arrange into extended bilayers, the cone
shaped phosphatidylethanolamine (PE) have a tendency to adopt HII phases and detergents with an
inverted cone shape assemble into micelles. When compared to these lipids, surfactin, a cyclic peptide
with a long fatty acyl chain [20], or the magainin 2 in-planar interfacial helix, use up much more space
in the head group than the hydrophobic core region of the membrane, thereby resembling detergents
(Figure 1A) [115]. A predictive model for the activities of linear cationic peptides, based on this and
previous considerations [58,72,115], has recently been elaborated for magainin 2 and melittin [116].
The wide variety of observations made with magainins and other cationic amphipathic
antimicrobial peptides has resulted in a number of seemingly contradictory models for their
interactions and supramolecular arrangement in bacterial membranes. These include toroidal
pores [117,118], the ‘carpet’ model where peptides cover the membrane surface at alignments parallel
to the surface (Figure 1B) [119], or random aggregates within the membrane [120]. Furthermore,
in electrophysiological recordings, channel-like events have been observed [59–61], whereas at high
peptide concentration, the formation of worm like structures, disk-shaped particles, or micelles have
been shown to occur [5,8,102,121]. A model should provide explanations for all of such a wide variety
of features.
It is important to note that the peptides are flexible and highly dynamic, and can adjust their
conformation and topology to the environment (e.g., [122,123]). In a related manner, lipid bilayers are
soft, can change shape and thickness, and are capable of adjusting to the presence of peptides or to
other environmental factors. To take into account the flexibility and dynamics of both the peptides
and the lipid membrane, the SMART model has been introduced, where ‘Soft Membranes Adapt
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and Respond, also Transiently’, in the presence of antimicrobial peptides (or other external stimuli).
As suggested by its name the model takes into account that lipid membranes can adapt to some extent
to the disruptive properties of the peptides, but undergo macroscopic phase transitions at higher
peptide concentrations, locally (Figure 1B) or globally. Notably, such phase changes can be transient;
for example, during the peptides crossing the membrane in order to equilibrate concentration gradients
between the outer and the inner leaflet of the membrane [66] (cf. above). Transient openings also occur
because the peptides diffuse laterally, thereby stochastic fluctuations in the local peptide-to-lipid ratio
occur locally [72]. Furthermore, phase diagrams are a convenient way to represent different modes of
interactions between the peptides and lipids where the supramolecular morphologies—such as bilayer,
wormholes, tubular structures, bicelle, micelle, or hexagonal phases—depend on the peptide-to-lipid
ratio, the detailed membrane composition, temperature, hydration, salt, pH, etc. [58]. For example,
for a number of peptides, in-plane or transmembrane topologies have been observed depending on pH,
hydration, peptide concentration, and lipid composition [42,124–126]. In a recent investigation using
dual polarization interferometry, surface plasmon resonance and atomic force microscopy, membrane
disordering, associated mass, and structural changes were followed in real-time revealing a number of
intermediate states including the lysis and recovery of membranes in the presence of magainin 2 [127].
Furthermore, changes in line tension have been suggested to be a common mechanism for a wide
variety of AMPs, observations that are in good agreement with the ideas of the SMART model [127,128].
Within this model at low peptide concentrations, the bilayer structure is maintained, where only
transient and local openings may appear. At higher peptide concentrations, an increasing strain on the
membrane packing results in openings [65] and macroscopic phase transitions of the peptide-lipid
assembly [115]. Thereby, the phase boundaries represent threshold concentrations where the peptides
change their level of activities. Thus, in-planar helix orientations agree with both the disruption of the
bilayer integrity at higher peptide-to-lipid ratios, as suggested by the ‘carpet model’ [119], and the
stochastic and transient rupture and closure of the membrane as revealed by electrophysiological
recordings when the peptide concentration is low [59–61].
In this context, it is noteworthy that magainins, carrying several positive charges, have been
shown to interact better with membranes carrying a negative surface charge from anionic lipids or
lipopolysaccharides. Indeed, such preferential association forms part of the explanation why these
peptides kill bacteria or tumor cells, which expose negative charges to the outside, and are non-toxic
to healthy eukaryotic cells (which are charge-neutral at their outer membrane leaflet) [129–133].
This preferential association can be dissected into an attractive electrostatic interaction that causes
a number of orders of magnitude of increase in local surface concentration along the negatively
charged surface, and a hydrophobic insertion characterized by partitioning coefficients that are of
similar order of magnitude for all membranes investigated (around 1000 M−1) [131,134]. Changes
in electrostatic interactions upon membrane association of multicationic antimicrobial peptides have
also been suggested to result in the release of peripheral membrane proteins, thereby exerting
antimicrobial activities [135].
Beyond increases in the apparent association constants through electrostatic interactions,
modulation of pore-forming and antimicrobial activities arises from the effect of anionic lipids
on the helical penetration depth and/or the topological equilibrium of the cationic peptides [136].
In addition, the formation of domains enriched in cationic peptides and acidic phospholipids has
been postulated from 2H solid-state NMR experiments using selectively deuterated lipids [137,138].
Electrostatics also play an important role for the interactions between peptides in lipid-mediated
mesophase-like arrangements along the membrane surface (Figure 1E) [74], an observation that
requires further investigation.
According to the SMART model, other cationic amphipathic molecules have the potential to
also exhibit antibacterial activities. Designed antimicrobial compounds should accumulate at the
surface of negatively charged bacteria and intercalate into their membranes at the level of the
phospholipid headgroups due to hydrophobic interactions. Interactions with healthy eukaryotic
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cells and toxicity should be avoided by tuning the composition to an overall moderate hydrophobicity.
Furthermore, the compounds should not insert too deeply into the lipid bilayer or span the lipid
membranes, but they should exhibit interfacial partitioning. Indeed, compounds with such features
have been designed and exhibit potent antimicrobials activities. These include short peptide
sequences [139–145], peptide mimetics [29–36], amphipathic polymers [37], or organic molecules
encompassing an aromatic ring system, a hydrophobic chain, and cationic functional groups [27].
2. Synergistic Enhancement of the Activities of Antimicrobial Peptides
The efficiency of antimicrobial compounds can sometimes be potentiated by applying them in
combination [50,146]. For example, mixtures of peptides with conventional antibiotics [37,145,147–150]
or ions [151] show synergistic enhancement. Whereas this enhancement can in some instances
be explained by one compound paving the way for the active antimicrobial ingredient [152],
other combinations, of e.g., dermaseptins or of bacteriocins, seem to interact more specifically to
exhibit synergistic activity [50,153]. Synergistic interactions involving magainin 2 have been detected
with PGLa [154], or with the cyclic beta-sheet peptide tachyplesin I [155].
The combination of magainin 2 and PGLa does not only show increased killing efficiency
of bacteria, but also a more efficient release of calcein from liposomes made from phospholipid
bilayers [75,156,157]. It is interesting to note that these peptides are naturally stored as a cocktail in
the skin of Xenopus laevis frogs. Thus, it seems that the naturally active synergism has been initially
destroyed by the standard analytical processes which involve separating the peptides from the complex
mixture and investigating each of them individually. In an early investigation on synergism, Masuzaki
et al. suggested that the pore formation rate of magainin is slower, but the pores are more stable than
those of PGLa [157]. In the mixture, synergism is a consequence of combining fast pore formation and
moderate stability. More recent work by Heerklotz and co-workers suggest that synergistic vesicle
leakage is a result of optimizing the size of the pores and their distribution among the liposomes [158].
They should be large enough, but at the same time sufficient in number to cause dye release from all
vesicles in the suspension. The propositions by both laboratories are related to the heterogeneity of the
peptide distribution in the membranes, and thereby related to the size of the vesicles or of bacterial
cells [158]. An additional ingredient to be considered is the possibility that one factor of the synergistic
mixture solubilizes the second one, thus increasing its availability [158].
In equimolar peptide mixtures, PGLa and magainin have both been found to exhibit an alignment
parallel to the membrane surface, provided that the membranes carry at least one unsaturation
per phospholipid [95,159,160], such as in E. coli lipid extracts [161] (Figure 1E–G). This helix
topology resembles those when magainin or PGLa are investigated individually by solid-state NMR
spectroscopy [38,95]. Contrasting data are obtained from lipids all carrying only saturated fatty acyl
chains where magainin remains oriented along the membrane surface, but PGLa, which is present
in the same mixtures, flips into transmembrane alignments [95,159]. Notably, in DMPC and in the
presence of PGLa, a 30◦ deviation from perfectly in-planar topology has also been observed for
magainin 2 [162]. Because fully saturated lipid mixtures do not represent the physiological membrane
composition well, it seems reasonable to assume an in-planar membrane topology for both peptides
(Figure 1E–G), and to use the context of the SMART model when mechanistic explanations for the
synergistic antibacterial activities are elaborated [43].
In order to develop a structural model of a supposed synergistic complex, experiments were
designed to delineate possible interactions sites between magainin 2 and PGLa. For example, modified
peptide sequences have been investigated. Early on, during dye release experiments from egg
PC/PG (1:1) liposomes, the F16W and E19Q mutants of magainin 2 were shown to exhibit reduced
synergistic activity, whereas the F5W mutation did not exhibit any effect [157]. It should be noted
however, that a quantitative comparison of synergism is hampered by variations that are observed
when different bacterial strains are compared to each other or to model membranes [75,163–165].
Importantly in a recent investigation Leber et al. showed that the synergism of calcein release
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activities from liposomes is not only a function of the absolute peptide concentration, but also of
the membrane intrinsic curvature and thus lipid composition [75]. Synergism is most pronounced
for membranes with high negative intrinsic curvature involving POPE lipids, and only apparent at
peptide concentrations ≥ 0.4 µM [75]. The synergistic factors were much reduced and even abolished
for calcein release experiments from POPC/POPG 3/1 where the peptides alone exhibit a high
activity [75]. In this context, it is interesting to note that in recent investigations, the antimicrobial
activity of magainin and PGLa derivatives leveled out at minimum inhibitory concentrations (MICs)
of about 1 µM [77,161]. Therefore, when only the synergistic factor is considered smaller values are
obtained for peptides that exhibit already high antimicrobial activity when investigated alone [161].
Similarly, when an α-helical sequence was modified by the insertion of prolines, the synergy with
conventional antibiotics increased as the antibacterial effectiveness of the peptides decreased [166].
An extensive mutagenesis study showed that the synergistic activity is abolished successively
when removing/inverting the negative charges at E19 and the carboxy terminus of magainin 2 [164].
As for PGLa the positively charged K15 and K19 sites had a favorable effect on the synergistic
enhancement [164]. Whereas making the hydrophobic face more hydrophobic increased the
antimicrobial efficiency of magainin 2, it had no effect on synergism [165]. Recently, the PGLa residues
G7, G11, and L18 have been found to be important for the synergistic enhancement of activities
between the two peptides [164]. Although it is interesting that glycines 7 and 11 form a GxxxG motif,
which has been shown to drive dimerization of transmembrane helical sequences in highly apolar
environments, the PGLa helix is localized at the interface rather than the hydrophobic interior of
the membrane [95,161]. Furthermore, there is no GxxxG motif on magainin 2 which could serve
as a counterpart for the formation of a magainin-PGLa heterodimer (Table 1). Therefore, to better
understand the role of the two glycines and of L18 in promoting synergistic activities, further structural
investigations are required.
Coarse-grain MD simulations over several microseconds encompassing 24 peptides (PGLa and
magainin) and 512 dilauroylphosphatidylcholine (DLPC; C12:0) lipids were also performed [167].
These simulations confirmed a tilting and deeper penetration of PGLa into the membrane,
without adopting a transmembrane orientation, whereas magainin stays on the bilayer surface.
The simulations reveal a clustering of the peptides by electrostatic interactions, concomitant with
a parallel alignment of the two helices, albeit without the explicit formation of pores [167]. An all-atom
MD simulation of the peptide mixture in DMPC and DMPG membranes, starting from transmembrane
tetramers was performed. The simulations suggest antiparallel helix arrangements in the 1:1
heterotetramer with stronger interactions in the heterodimer than in the homodimer. Plausible
interactions could occur between the S8 and E19 residues of magainin and K12 and K19 of PGLa [108].
Though in the mixture of both peptides the tilt angle of PGLa is reduced when compared to PGLa
alone, a large variety of helix alignments relative to the normal membrane still persists [108].
Fluorescence spectra were used to derive constants for the membrane association of magainin
and its interactions with PGLa in its membrane. Favorable PGLa-magainin interaction energies were
obtained when investigated in egg-PG membranes, where the exact value depends on the assumed
numbers of peptides involved in the process [157]. Energies for homo- and heterodimer formation
based on the midpoints of the concentration-dependent transition of PGLa from an in-planar to
a transmembrane alignment were extracted in a later investigation [168]. Notably, this transition only
occurs in fully saturated membranes, but not in the presence of lipid unsaturation, as they occur in
biological membranes. One should also be aware that these quantities are associated with a specifically
chosen interaction model (cf. reference [157]). Furthermore, they represent a multitude of interaction
terms that change during the topological transition; thus the energies involved include the transfer
of residues in between polar and non-polar membrane environments, and energies associated with
disordering the lipids or local changes in membrane phase, direct interactions between the peptide
and the lipid as well as between peptides [104,125]. In this context, it should be noted that fluorescence
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resonance energy transfer (FRET) experiments did not reveal a strong interaction between magainin 2
and PGLa when associated to POPE/POPG 3/1 or POPC/POPS 3/1 membranes [77].
Isothermal Titration Calorimetry (ITC) has already provided valuable insights into the
thermodynamics or membrane association of magainin 2 and PGLa [56,131,134,169–171]. In order to
further explore possible interactions with membranes, large unilamellar vesicles (LUVs) made of
POPE/POPG 3/1 at pH 7 were prepared as a model system for bacterial membranes. In this context,
the interactions of both peptides individually and as a mixture were investigated (Figure 2).
Interestingly, only endothermic enthalpies (∆H) were observed when each peptide was titrated into
the lipid suspension individually (Figure 2A,B) while the peptide mixture revealed a considerably
more complex time trace of reaction enthalpies (Figure 2C), suggesting additional modes of interaction.
Additional exothermic enthalpies are observed for peptide to lipid molar ratios > 1.5%, i.e. for times of
injections t > 1000 s. When compared to previous investigations with 30 nm small unilamellar vesicles
(SUVs) [131,134,169,170], the reaction enthalpies of magainin 2 and PGLa with 100 nm LUVs, also used
here, are relatively small [171]. A quantitative analysis of the ITC traces (Figure 2D,E) reveals enthalpies
of 3–4 kcal/mol for PGLa and magainin, respectively, entropies of 40 cal·mol−1·K−1, and apparent
membrane association constants in the 106 M−1 range (apparent stoichiometry P/L ≈ 1.7 mol %).
Although different experimental conditions have been chosen for the experiments shown in Figure 2
when compared to previous investigations, a closely related stoichiometry becomes apparent [134].
By comparing the enthalpy produced from titration of the mixed peptide solution with the combined
data from the individual injections, a ∆H in the range of −2 kcal/mol remains for additional processes
in the peptide mixture (Figure 2F).
Circular dichroism (CD) analysis (not shown) combined with Dynamic light scattering (DLS)
measurements were performed under the same conditions (Figure 3). Both peptides adopt largely
α-helical conformations while they interact with the membrane. At the same time, large supramolecular
structures form, suggesting the flocculation of the vesicles in the simultaneous presence of both
peptides, similar to observations made with a designed model antimicrobial peptide [76,172].
Previously, a reduction in bilayer repeat distance of mechanically oriented membranes in the presence
of magainin and magainin/PGLa, but not PGLa alone, has been observed [103]. It seems possible that
these previous observations are related to the interbilayer interactions observed in our ITC and DLS
experiments (Figures 2 and 3). Figure 1F schematically illustrates the possible role of peptide–peptide
interactions during such processes. Membrane pore formation by the AMP mastoparan-X and
micellation at much higher P/L ratio was previously reported from ITC data [173].
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D
Figure 2. Isothermal Titration Calorimetry measurements of large unilamellar vesicles (LUVs) made of
palmitoyl-oleoyl-phosphatidylethanolamine/ palmitoyl-oleoyl-phosphatidylglycerol POPE/POPG
(3/1) at 440 µM total lipid concentration, into which solutions of 85 µM magainin 2 (A), 140 µM PGLa
(B), and the equimolar mixture of PGLa and magainin 2 at 105 µM total peptide concentration (C) have
been injected successively. Buffer: 10 mM Tris-HCl, pH 7, 100 mM NaCl. The inserts show close-ups
of the regions t > 2215 s. The fittings of the data with a single binding site model are displayed as
solid lines in panels D–F. The open circles in panel F show the difference of the heat of reactions when
comparing the mixture of peptides with the sums obtained from the magainin 2 and PGLa titrations
(i.e., half the intensities of the fitted curves shown in panels D and E, dashed line). The values of the
enthalpies (∆H), entropies (∆S), binding constant (K), and apparent stoichiometry (N) are reported in
the corresponding graphs.
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Figure 3. Dynamic light s cattering (DLS) size measurement of LUVs made of 440 µM POPE/POPG
(3/1) and incubated ith againin 2 (long dashed line), PGLa (short dashed line) or an equimolar
mixture of PGLa and magainin 2 (continuous line) in 10 mM Tris-HCl buffer pH 7. The vesicles were
made by mechanical extrusion through a 100 nm pore filter and the peptide to lipid ratio was kept
constant at P/L = 3.6% for all tree easure ents (this corresponds to the same condition for peptide
injection at t ≈ 2030 s in Figure 2C). The averaged hydrodynamic radius < RH > is indicated in the
upper right of the graphs.
In order to further explore pos ible interactions betwe n membrane-as ociated PGLa and
magainin , cro s linking experiments hav been performed with peptides carrying a GGC
extensions [174]. This ork sho s that when added to egg PC/PG(1/1) lipid m mbr nes, parall l
dimers preferentially form [174]. Based on this dat , covalent dimers linked through C-terminal
GGC extensions w re prep red, and all the (PGLa-GGC)2 and (magainin-GGC)2 homodimers,
as well as the magainin-G C/PGLa-GGC het odimer were more active in calcein release from
POPE/POPG 3/1 liposomes, than with the same amount of unmodified peptides in a mixtu e [75].
However, whe investigated in POPC/cholesterol 3/1 mixtures, q ite diff rent results were obtained
because nly the PGLa-homodimer nd the PGLa-magainin heterodimer, but not the individual
peptides or their mixture, showed significant release activiti s [75]. Thus, the increased activities of
the dimers seem not to be related to a particular structure formed by the combination of PGLa and
m gainin 2, but rather they reflect the incr as d membrane-perturbing pro rties of larger peptide
aggregates [175–177]. Notably, the co parison of di r d monomer antibacterial activities of wild
type mag inin and PGLa nd their derivatives are complicated by the fact that they are already
increased by the GGC extensions [161,163].
There are only few biophysical investigations that elucidate the mechanisms of the synergism
observed for membrane-associated amphipathic peptides. Nevertheless, our view has already moved
from models of heterooligomeric transme brane bundles to helices that someh w play together when
being orie ted at th membran surf c . Thereby t situation resembles early rese rch on c tionic
amphipathic pe tides which had been found to reside at the m mbrane interf c rather than forming
transmembrane helical bundles [178,179]. From there the field has developed [46,58,180,181] and after
years of research still bears surprises [74]. It can be expected that our views on synergism will evolve
in a related manner [75,95,158,159].
Recently it has been shown that synergism is most pronounced when the peptides alone have
not reached their optimum [75,161]. In good agreement with the SMART model [43], the peptide
sequence and the membrane lipid composition are both important elements of synergy [75,161].
Thus, synergistic enhancements of calcein release only becomes apparent in membranes with intrinsic
negative curvature and negative surface charge [75]. It is suggested that PGLa preconditions the
more densely packed POPE membranes by softening up its interface, thus magainin, being more
amphipathic, can penetrate deeper and be more active (Figure 1E) [75]. Furthermore, it is of
interest for our understanding of the mechanism of action of antimicrobial peptides per se and the
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synergism they develop in their membrane associated state, that fluorescence quenching experiments
are indicative of mesophase arrangements of both peptides along the membrane interface and
a more densely packed supramolecular arrangement when both peptides are present in equimolar
quantities [74,77] (Figure 1D,G).
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